To assess the renal benefits of combined angiotensin-converting enzyme inhibition and calcium antagonism, we studied the antihypertensive and renoprotective effects of temocapril (TMP) alone or in combination with azelnidipine (AZN) in a spontaneously hypertensive rat (SHR) remnant kidney model of chronic renal failure. Male 5/6-nephrectomized SHR/Izumo rats were randomly assigned to receive vehicle (control group), TMP (TMP group; 10 mg kg 1 day 1 ), AZN (AZN group; 3 mg kg 1 day 1 ), or both (TMP AZN group) orally for 12 weeks. Systolic blood pressure (SBP) and urinary excretion of albumin (UalbV) were measured every 2 weeks. At the end of the experiment, serum creatinine (Scr), heart weight (HW), and blood urea nitrogen (BUN) levels were measured and the remnant kidneys were examined to determine the index of glomerular sclerosis (IGS). SBP and UalbV in the control group increased progressively throughout the experimental period. TMP, AZN, and TMP AZN blocked the development of hypertension. TMP AZN did not enhance the antihypertensive effects of either TMP or AZN used singly. TMP, AZN, and TMP AZN all significantly decreased the UalbV, Scr, BUN, and HW/body weight (BW) ratio. The level of UalbV and the HW/BW ratio in the TMP AZN group were significantly lower than those in the TMP and AZN groups, and the level of Scr in the TMP AZN group was significantly lower than that in the TMP group. TMP, AZN, and TMP AZN all significantly protected against an increase in the IGS. The IGS in the TMP AZN group was significantly lower than that in the TMP and AZN groups. These results indicate that both TMP and AZN have antihypertensive and renoprotective effects in this model. They also suggest that simultaneous administration of TMP and AZN provides greater renoprotective effects than TMP alone. (Hypertens Res 2002; 25: 447-453)
Introduction
Systemic hypertension is a well-known cause of progressive suggested to be responsible for the progressive deterioration of renal function (3, 4) .
Antihypertensive therapy reduces the rate of decline of renal function in established progressive renal disease (5, 6) . Recent evidence suggests that the ability of antihypertensive therapy to protect the kidneys relates largely to the glomerular hemodynamic consequences of therapy (7) . Not all antihypertensive regimens afford equal renal protection, and agents that control glomerular hypertension may provide maximal protection to the kidney at risk for progressive glomerular injury (7) .
Angiotensin-converting enzyme inhibitors (ACEIs) have been shown to be protective against hyperfiltration damage in remnant kidney nephrons in chronic renal failure (7, 8) , and a meta-analysis indicated that ACEIs have the twin beneficial effects of reducing proteinuria and preserving renal function (6) .
On the other hand, calcium antagonists have been shown to reduce glomerular injury in a rat remnant kidney model of chronic renal failure (9) , and to be effective antihypertensive agents for treating hypertensive patients with chronic renal failure (10, 11) .
The results of clinical trials suggest that ACEIs and calcium antagonists may have comparable renal protective effects (12) (13) (14) . These beneficial effects of treatment with ACEIs and calcium antagonists raise the question of whether any additional benefit can be derived from combination therapy with both classes of agents.
Temocapril (TMP) (Sankyo Co., Tokyo, Japan) is a longacting ACEI without a sulfhydryl group, and is the ester prodrug of the pharmacologically active diacid metabolite, temocaprilat. TMP is excreted mainly into the feces with a sustained potent action in animal experiments (15) .
Azelnidipine (AZN) (Sankyo Co.), ( )-3-(1-diphenylmethylazetidin-3-yl) 5-isopropyl 2-amino-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridine-dicarboxylate, is a newly developed dihydropyridine calcium antagonist that stands out by virtue of its prolonged duration of action. The efficacy of AZN as an antihypertensive agent has been shown in experimental models (16) (17) (18) .
Despite the above findings, the effects of combination therapy with TMP and AZN on progressive albuminuria and glomerular sclerosis in a spontaneously hypertensive rat (SHR) remnant kidney model of chronic renal failure have not been studied. Therefore, to assess the combined effects of these novel agents, we studied the antihypertensive and renoprotective effects of AZN and TMP alone and in combination in SHR with renal ablation.
Methods
Thirty-six male SHR/Izumo rats (Funabashi Farm, Chiba, Japan), 5 weeks old, were subjected to 5/6-nephrectomy by removal of the left kidney and infarction of two-thirds of the right kidney. This subtotal nephrectomy was performed under ether anesthesia. The right kidney was exposed via a flank incision, and the two poles of the right kidney were excised by encircling them with loops of ligatures and then tightening the loops, and then the incision was closed. Two weeks later, the left kidney was removed in total after exposure via a flank incision, and then the flank incision was closed. Throughout the study, rats were housed in a metabolic cage designed to prevent feces-urine contact (model ST; Sugiyamagen, Tokyo), in a humidity-and temperature-controlled room (55 10% and 22 2˚C, respectively) with a 12-h light/dark cycle. The rats were fed a regular diet (Funabashi F2 (0.19 wt% sodium, 0.25 wt% potassium and 20.8 wt% protein); Funabashi Farm (Funabashi, Japan), and had free access to tap water.
One week after ablation, when the rats were 8 weeks old, baseline measurements of body weight (BW), systolic blood pressure (SBP), urine volume (UV) and urinary excretion of albumin (UalbV) were made. The rats were then randomly assigned to one of four groups. The control group (n 9) was given vehicle alone. The TMP group (n 9) received TMP 10 mg/kg/day. The AZN group (n 9) received AZN 3 mg/kg/day. And the TMP AZN group (n 9) received a combination of both TMP 10 mg/kg/day and AZN 3 mg/kg/day. TMP and AZN were mixed with 0.5% carboxymethyl cellulose before administration and administered by daily gavage at 9 AM for 12 weeks. Oral administration of TMP at 10 mg/kg/day for 21 weeks lowered systemic blood pressure of conscious SHR significantly from week 1 and throughout the rest of the 21-week observation period (19) . Single oral administration of AZN at 3 mg/kg produced a long-lasting decrease of systemic blood pressure in conscious SHR (18) .
Twelve weeks after the initiation of treatment, the rats were killed by decapitation and trunk blood was collected in polyethylene tubes for the determination of serum creatinine (Scr) and blood urea nitrogen (BUN). The heart was removed and weighed, and the heart weight (HW)/BW ratio was calculated. The remnant kidneys were removed and portions were fixed in 10% neutral buffered formalin. Paraffin sections (3µm thick) were cut and stained with haematoxylin and eosin, periodic acid-Schiff's reagent and Masson's trichrome and Azan Mallory. An investigator blinded to the group assignments examined all of the sections. High-power fields were used to examine for evidence of focal sclerosis (20, 21) . For calculating focal glomerular sclerosis, 150-200 glomeruli from each stained section were examined. The degree of sclerosis in each glomerulus was subjectively graded on a scale of 0 to 4 as follows: Grade 0, no change; Grade 1, sclerotic area less than or equal to 1/4 of the glomerulus or the presence of distinct adhesion between the capillary tuft and Bowman's capsule; Grade 2, sclerosis of 1/4 to 1/2 of the total glomerular area; Grade 3, non-global sclerosis of more than 1/2 of the glomerulus; Grade 4, global sclerosis. The index of glomerular sclerosis (IGS) was calculated using the following formula (21) (22) (23) :
where N is the number of glomeruli at each grade of sclerosis. SBP was monitored every 2 weeks in conscious rats by the indirect tail-cuff method (UEDA UR 1000; Ueda Industries Co., Tokyo, Japan) without anesthesia between 1 PM and 3 PM. The SBP measured using this method correlates well with that measured using a direct method (24) . UV and BW were measured gravimetrically, and urine was collected every 2 weeks and immediately stored at 20˚C until use. For the determination of UalbV, we used an enzyme-linked immunosorbent assay (NEPHRAT; Exocell, Inc., Philadelphia, USA). BUN and Scr were measured using a standard autoanalysis technique (Synchron CX-3; Clinical Systems, Beckman Coulter Inc., Fullerton, USA).
Values are expressed as the means SEM. With respect to BUN, Scr, and the HW/BW ratio, comparisons between groups were performed using the unpaired Student's t-test. For SBP and UalbV, comparisons between groups were performed by analysis of variance (ANOVA) with repeated measures over the duration of the study. Statistically significant differences on each day were assessed between groups by the unpaired Student's t-test. Values of p 0.05 were considered to indicate statistical significance. With respect to the IGS, comparisons between groups were performed using the non-parametric Mann-Whitney's U test. The statistical analysis was performed using STATVIEW 5.0 software (Abacus Concepts Inc., Berkeley, USA).
The study conformed to the principles for the use of live animals as outlined in the Declaration of Helsinki and those of the ethical committee of Tohoku University Graduate School of Medicine.
Results
The SBPs of the rats during the 12-week experimental period are shown in Fig. 1 . The SBP in the control group increased progressively throughout the experimental period. TMP, AZN, and TMP AZN each induced a similar and significant decrease in SBP compared with the control group (repeated measures ANOVA, p 0.001). Twelve weeks after the initiation of treatment, the SBPs were 265 7, 156 3, 160 7, and 154 1 mmHg in the control, TMP, AZN, and TMP AZN groups, respectively (n 9 each).
The values of UalbV of the rats during the 12-week experimental period are shown in Fig. 2 . UalbV in the control group was increased progressively throughout the experimental period. TMP, AZN, and TMP AZN decreased the level of UalbV significantly compared with that in the control group (repeated measures ANOVA: p 0.001 TMP vs. control; p 0.001 AZN vs. control; p 0.0001 TMP AZN vs. control). Furthermore, the level of UalbV in the TMP AZN group was significantly lower than that in the TMP or AZN groups (repeated measures ANOVA: p 0.05 TMP vs. TMP AZN; p 0.01 AZN vs. TMP AZN).
The levels of Scr in the TMP, AZN, and TMP AZN groups were significantly lower than that in the control group (unpaired t-test: p 0.05 TMP vs. control; p 0.05 AZN vs. control; p 0.01 TMP AZN vs. control) ( Fig. 3a) . Furthermore, the level of Scr in the TMP AZN group was significantly lower than that in the TMP group (unpaired t-test; p 0.01) (Fig. 3a) .
The BUN values in the TMP, AZN, and TMP AZN groups were significantly lower than that in the control group (unpaired t-test: p 0.01 TMP vs. control; p 0.05 AZN vs. control; p 0.01 TMP AZN vs. control) (Fig. 3b) .
The HW/BW ratios in the TMP, AZN, and TMP AZN groups were significantly lower than that in the control group (unpaired t-test: p 0.01 TMP vs. control; p 0.01 AZN vs. control; p 0.0001 TMP AZN vs. control) ( Fig. 3c ). Furthermore, the HW/BW ratio in the TMP AZN group was significantly lower than that in TMP and AZN groups (unpaired t-test: p 0.05 TMP AZN vs. TMP; p 0.01 TMP AZN vs. AZN) (Fig. 3c) .
The control group demonstrated glomerular structural lesions, including mesangial expansion and segmental sclerosis.
The IGS values in the TMP, AZN, and TMP AZN groups were significantly lower than that in the control group (non-parametric Mann-Whitney's U test: p 0.05 TMP vs. control; p 0.05 AZN vs. control; p 0.001 TMP AZN vs. control) (Fig. 4 ). In addition, the IGS in the TMP AZN group was significantly lower than that in the TMP or AZN group (non-parametric Mann-Whitney's U test: p 0.001 TMP AZN vs. TMP; p 0.05 TMP AZN vs. AZN) ( Fig. 4) .
Discussion
In the present study, a model combining SHR with reduced renal mass was chosen because the functional and structural nephropathy is known to develop faster in this model than in a normotensive model with reduced renal mass (25) . In the intact SHR, the glomerulus is protected from high systemic blood pressure by relative afferent arteriolar vasoconstriction. Despite severe systemic hypertension, the superficial nephrons of the SHR exhibit relatively low values for glomerular capillary plasma flow rate, and normal values for glomerular capillary pressure and single-nephron glomerular filtration rate, with relative resistance to focal and segmental glomerular sclerosis (2) . However, renal ablation in the SHR results in lowering of afferent arteriolar resistance in the remaining kidney, allowing transmission of systemic hypertension and elevation of glomerular capillary pressure (2) . Therefore, this hemodynamic alteration is associated with a sharp increase in values for proteinuria and acceleration of . control) . The HW/BW ratios in the TMP, AZN, and TMP AZN groups were significantly lower than that in the control group (unpaired t-test: p 0.01 vs. control; p 0.0001 vs. control). The HW/BW ratio in the TMP AZN group was significantly lower than that in the TMP or AZN groups (unpaired t-test: p 0.05 vs. TMP; p 0.01 vs. AZN).
Fig. 3. (a) Serum creatinine (Scr), (b) blood urea nitrogen (BUN) and (c) heart weight (HW)/body weight (BW) ratio. Rats received vehicle alone (control), temocapril alone (TMP), azelnidipine alone (AZN), or both TMP and AZN (TMP AZN
focal and segmental glomerular sclerosis (2) . In the present study, untreated control rats demonstrated progressive albuminuria, which is consistent with the development of hypertension, as well as glomerular structural lesions characterized by mesangial expansion and segmental sclerosis.
TMP decreased SBP efficiently, and reduced the values of IGS, Scr, BUN, and UalbV. Moreover, AZN blocked the development of hypertension, retarded the progression to glomerulosclerosis and blunted the rise in albuminuria. These results indicate that both TMP and AZN have the potential to preserve renal function and to lessen renal damage in this rat model.
The mechanism underlying the renoprotective effects of TMP may be a reduction in intraglomerular capillary pressure. Although we did not assess intraglomerular hyperfiltration in the present experiment, angiotensin II is known to constrict the efferent arterioles, and thus to help maintain the glomerular capillary pressure and glomerular filtration (26) (27) (28) . Removal of angiotensin II by ACEIs would therefore reduce the capillary pressure and glomerular filtration. In their micropuncture study, Lafayette et al. (29) reported that enalapril was effective in reducing the systemic and glomerular transcapillary pressure in rats after renal ablation.
In addition to efferent vasoconstriction, angiotensin II have many other actions in the kidney, including effects on mesangial cell contraction and macromolecular uptake through the mesangium (30) , glomerular permeability to pro-teins (31) , tubular sodium reabsorption (32) , and vasa recta blood flow (33) , all of which might modulate the progression of the intrarenal pathology in renal failure. Therefore, ACEIinduced inhibition of the production of angiotensin II may cause many changes other than those seen in the glomerular hemodynamic variables, some of which may contribute to the renal protective effects of ACEIs. For example, Amann et al. (34) reported that enalapril inhibits the compensatory glomerular enlargement and the increase in mesangial cell number and activation, with a concomitant reduction in the development of glomerulosclerosis in subtotal nephrectomized rats.
Calcium antagonists are known to dilate preglomerular vessels (35) (36) (37) (38) . Therefore, in the absence of a reduction in the systemic blood pressure, the glomerular capillary pressure would remain constant or might even rise, resulting in increased glomerular pre-load in response to the calcium antagonists. In contrast, in the presence of a predominant change in the systemic blood pressure, the decrease in perfusion pressure would cause the glomerular capillary pressure to fall by an increment exceeding the increase in glomerular pre-load caused by the dilatation of the afferent arteriole by the calcium antagonists. The mechanism underlying the renoprotective effects of AZN may be the decrease in the glomerular capillary pressure due to the efficient reduction in the systemic blood pressure. In addition to preglomerular vasodilatation, calcium antagonists have many other actions in the kidney, including effects on angiotensin II-induced glomerular contraction (39) , angiotensin II-mediated stimulation of glomerular (mesangial) cell growth (40) , angiotensin II-induced antinatriuresis (41) , and renal tubule handling of sodium and water (42) . However, the precise mechanisms of the renoprotective effects of calcium antagonists remain to be elucidated.
In the present study, TMP, AZN, and TMP AZN each induced a similar and significant decrease in SBP compared with the control group. However, TMP AZN had greater renoprotective effects than either TMP alone or AZN alone. Although it may be beneficial to lower systemic blood pressure even if the reduction is extremely small, it is likely that both TMP and AZN have specific tissue effects that are not related to the arterial blood pressure reduction. Possibly, TMP AZN dilated both pre-and postglomerular vessels and thereby reduced the glomerular capillary pressure more effectively than either of the monotherapies. Münter et al. (43) reported that the combined administration of trandolapril and verapamil in doses that did not lower the systemic blood pressure caused a marked reduction in proteinuria and glomerulosclerosis in stroke-prone SHR. And in the present study, we observed similar renoprotective effects by combination therapy with a novel ACEI and a novel calcium antagonist in another model of chronic renal failure.
In humans, combination therapy with calcium antagonists and ACEIs has been shown to reduce blood pressure more than either drug alone (44, 45) . In the present study, howev-
Fig. 4. Index of glomerular sclerosis (IGS). Rats received vehicle alone (control), temocapril alone (TMP), azelnidipine alone (AZN), or both TMP and AZN (TMP AZN).
Values are expressed as the means SEM. The IGS value in the TMP, AZN, and TMP AZN groups were significantly lower than that in the control group (non-parametric Mann-Whitney's U test: p 0.05 vs. control; p 0.001 vs. control). The IGS value in the TMP AZN group was significantly lower than that in the TMP or AZN group (non-parametric Mann-Whitney's U test: p 0.001 vs. TMP; p 0.05 vs. AZN). er, TMP AZN did not enhance the antihypertensive effects of either TMP or AZN used singly. The reason why the combination did not produce an additional significant reduction in systemic blood pressure is unclear. TMP might have little additive effect on systemic blood pressure in this model with severe hypertension already on treatment with AZN, in particular when the AZN is maximally effective.
In conclusion, the antihypertensive and renoprotective effects of TMP and AZN were demonstrated in an SHR remnant kidney model of chronic renal failure. Moreover, combination treatment with an ACEI and a calcium antagonist had additional renoprotective effects in this rat model. Although ACEIs and calcium antagonists have been thought to be the best antihypertensive drugs for treating hypertension with chronic renal failure, the combined use of an ACEI and a calcium antagonist to protect against the progression of chronic renal failure might yield greater benefits than antihypertensive therapy with either component alone.
